Dynavax Technologies (NASDAQ:DVAX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday.

Several other research firms also recently commented on DVAX. William Blair reiterated an “outperform” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a report on Wednesday, August 9th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $28.00 price objective (up from $26.00) on shares of Dynavax Technologies in a report on Monday, September 25th. Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Cowen reiterated a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a report on Friday, November 3rd. Finally, Cantor Fitzgerald lifted their price objective on Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $25.17.

Dynavax Technologies (NASDAQ:DVAX) traded down $1.60 on Friday, hitting $18.40. The stock had a trading volume of 1,908,637 shares, compared to its average volume of 2,297,730. Dynavax Technologies has a 12-month low of $3.70 and a 12-month high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.28 million. During the same quarter in the previous year, the firm earned ($0.90) EPS. Dynavax Technologies’s quarterly revenue was down 68.8% compared to the same quarter last year. research analysts expect that Dynavax Technologies will post -1.72 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in the business. Vident Investment Advisory LLC grew its stake in shares of Dynavax Technologies by 3.1% during the 3rd quarter. Vident Investment Advisory LLC now owns 150,258 shares of the biopharmaceutical company’s stock valued at $3,231,000 after purchasing an additional 4,553 shares during the period. First Republic Investment Management Inc. bought a new stake in shares of Dynavax Technologies during the 3rd quarter valued at about $2,414,000. Crawford Lake Capital Management LLC bought a new stake in shares of Dynavax Technologies during the 3rd quarter valued at about $1,481,000. California State Teachers Retirement System grew its stake in shares of Dynavax Technologies by 12.0% during the 3rd quarter. California State Teachers Retirement System now owns 97,417 shares of the biopharmaceutical company’s stock valued at $2,094,000 after purchasing an additional 10,412 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its position in shares of Dynavax Technologies by 29.9% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 235,310 shares of the biopharmaceutical company’s stock valued at $5,060,000 after buying an additional 54,149 shares in the last quarter. Institutional investors and hedge funds own 70.61% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Downgrades Dynavax Technologies (DVAX) to Sell” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/03/valuengine-downgrades-dynavax-technologies-dvax-to-sell.html.

About Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Stock Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related stocks with our FREE daily email newsletter.